加载中
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
收盘时
US$23.52
−US$0.72 · -2.97%
盘后
US$23.30
−US$0.22 · -0.94%
10月13日 17:11 ET
盘中时间采用ET。市场数据可能有所延迟。
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
日内区间
当前US$23.52
52周区间
当前US$23.52
盘中时间采用ET。市场数据可能有所延迟。
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
日内区间
当前US$23.52
52周区间
当前US$23.52
| 项目（USD） | 2025财年 |
|---|---|
| 营收 | 7421.1万 USD |
| 销货成本 | 3250.6万 USD |
| 毛利 | 4170.5万 USD |
| 研究与开发 | 3747.1万 USD |
| 销售、一般及管理费用 | 3556.8万 USD |
| 营业费用 | 7303.9万 USD |
| 利息收入 | 216万 USD |
| 利息支出 | 40.1万 USD |
| 折旧和摊销 | 386.4万 USD |
| 营业利润 | −3133.4万 USD |
| 净利润 | −2981.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$33.50
上涨空间 42.43%报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG2712.76万1.32%22.19亿 USD0.75%US$48.51-1.96%
Vanguard Morningstar Total Stock Market ETFVTI978.07万0.00%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM828.33万0.01%787.4亿 USD0.19%US$276.71-0.43%
Vanguard Extended Market ETFVXF418.59万0.00%954亿 USD0.05%US$232.54-0.42%
Vanguard Russell 2000 ETFVTWO233万0.01%180亿 USD0.06%US$111.77-0.45%
iShares Russell 2000 Growth ETFIWO207.63万0.02%139.17亿 USD0.24%US$351.1-0.74%
Schwab U.S. Small-Cap ETFSCHA152.62万0.01%217.13亿 USD0.03%US$32.56-0.31%
iShares Russell 2000 Value ETFIWN97.44万0.01%137.49亿 USD0.24%US$210.99-0.05%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Value ETFIWNAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
